TeraImmune

TeraImmune Inc. is a biotechnology company dedicated to developing innovative immune cell therapies. The company is utilizing a dual Treg manufacturing platform, consisting of natural regulatory T cells (Tregs) isolated from patients (TRGable™) and induced Tregs converted from patients' T effector (Teff) cells (TREGing™). Its Treg platform technology is designed to suppress unwanted immune responses. The company has expanded its pipeline to include allogeneic or off-the-shelf Tregs derived from umbilical cord blood for the treatment of dermatological conditions such as atopic dermatitis. The selective expansion of Tregs with target-specific receptors can suppress unnecessary immune responses in patients with autoimmune diseases without side effects.